Dear LabPulse reader:
This week, advances in blood-based diagnostics for neurodegenerative disorders were at the forefront of the news. Sunbird Bio shared new data from a study on its blood-based technology for the diagnosis of Parkinson's disease and other neurodegenerative diseases, while a team at the University of Pittsburgh shared their findings for Alamar Biosciences’ NULISASeq CNS disease panel 120, which can measure more than 100 biomarkers linked to Alzheimer’s disease.
Caris Life Sciences garnered FDA approval for its MI Cancer Seek for use as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted treatments across a range of cancers.
Additionally in diagnostics, in its newly released Final Rule for the 2025 Medicare Physician Fee Schedule, the U.S. Centers for Medicare and Medicaid Services (CMS) updated its coverage for a complete colorectal cancer (CRC) screening to include Medicare-covered blood-based biomarker CRC screening tests.
In other innovations, digital pathology firm Aignostics raised $34 million in funding to advance their AI-driven models designed to support drug discovery, translational research, clinical trials, and CDx development.
Thanks for reading.
